 |
Photo = CJ CheilJedang |
[Alpha Biz= Reporter Kim Sangjin] CJ CheilJedang, a key subsidiary of CJ Group, has responded to speculation about the sale of its bio division, stating that no specific decisions have been made.
According to the Financial Supervisory Service on the 19th, CJ CheilJedang announced, "We are reviewing various strategic options regarding the bio business, but no concrete decisions have been finalized." The company added, "We will make a follow-up disclosure when specific details are determined or within one month."
Reports suggest that CJ CheilJedang is considering the sale of its bio division. Financial industry analysts estimate the division's value at approximately 6 trillion KRW (around $4.5 billion).
AlphaBIZ Kim SangJin(letyou@alphabiz.co.kr)
